New Study Finds Nicotine E-cigarettes Safer Than Traditional Cigarettes.

Aug.12.2022
New Study Finds Nicotine E-cigarettes Safer Than Traditional Cigarettes.
New research shows that nicotine e-cigarettes produce fewer harmful effects on cells than cigarettes, reducing cardiovascular disease risk.

A new in vitro study has shown that aerosols from nicotine electronic cigarettes do not produce the cellular effects caused by cigarette smoke, which can lead to blood vessel damage and a range of heart diseases. It also found that aerosols from heated tobacco products produce far fewer adverse cellular effects compared to cigarettes. This research is crucial as smokers are two to four times more likely to suffer from heart disease than non-smokers, and one-fifth of smoking-related deaths are caused by cardiovascular diseases.


However, the significance of this study published last month goes beyond these specific findings. It is part of a replication initiative aimed at replicating the most famous studies conducted by tobacco companies to independently evaluate their scientific validity. The replication project aims to replicate ten international scientific studies, comparing the toxicity levels of traditional cigarette smoke, e-cigarettes, and heated products using human cells. The replication project is working to replace junk science with reliable data.


The project is being operated by the Center of Excellence for the Acceleration of Harm Reduction (CoEHAR). The organization is headquartered in Sicily and has previously exposed deep methodological flaws in highly cited e-cigarette studies. It is now working to replace junk science with reliable data while recognizing that industry-funded research is often controlled by tobacco and ignored by broader public health organizations. Dr. Riccardo Polosa, founder of CoEHAR, told Filter: "By replicating the results of tobacco-funded research on e-cigarettes and heated tobacco products, we demonstrate that these results are reliable and trustworthy.


A new study conducted by an international research group affiliated with CoEHAR has been carried out in independent laboratories in Indonesia, Oman, Russia, Serbia, Greece, and the United States. This finding challenges the repeated claims by medical associations that using e-cigarettes or heated tobacco products is equally as dangerous as smoking, and advises patients to quit smoking and not switch. The American Heart Association stated on their website that "anyone who says e-cigarettes are safe is blowing smoke.


Researchers replicated a 2017 study by scientists at British American Tobacco (BAT), which showed that inhibition of endothelial cell migration caused by cigarette smoke, which lines the interior of the heart and blood vessels, is not caused by aerosol exposure from electronic cigarettes. "Our study again challenges the view that e-cigarettes or heated tobacco cause similar harm to combustible cigarettes," the Replica study, which used Vype ePen3, and heated tobacco products Glo Pro and IQOS 3 Duo, confirmed the results of the BAT study. It validates that transitioning to safer nicotine products can reduce harm and save lives.


An interesting fact is that switching to smoke-free products can decrease blood vessel damage and prevent the likelihood of smoking-related diseases such as atherosclerosis and high blood pressure. "Our study once again challenges the notion that e-cigarettes or heated tobacco cause similar damage to combustible cigarettes," said Dr. Massimo Caruso, lead author of the study and co-director of the replication project.


Statement


This article is compiled from third-party information and is intended for industry communication and educational purposes.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the truthfulness and accuracy of the article's content. The translation of this article is only for internal industry communication and research purposes.


Due to limitations in our translation abilities, the translated article may not accurately convey the same meaning as the original. Please refer to the original article for the most accurate information.


2FIRSTS maintains complete alignment with the Chinese government regarding any domestic, Hong Kong, Macau, Taiwan, or foreign-related statements and positions.


The copyright for compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Imperial Brands 2025 Interim Report: NGP Net Revenue Up 15.4%, Pulze 3.0 Heated Tobacco Device to Launch in H2
Imperial Brands 2025 Interim Report: NGP Net Revenue Up 15.4%, Pulze 3.0 Heated Tobacco Device to Launch in H2
Imperial Brands has released its 2025 half-year results, reporting total revenue of £14.604 billion, down 3.1% year-on-year. Net revenue from next-generation products (NGPs) rose by 15.4%. The company's oral nicotine brand Zone has seen early success in the U.S. market, and development of the Pulze 3.0 heated tobacco device is complete, with a launch planned in key markets during the second half of the year.
May.14 by 2FIRSTS.ai
PMI International Launches Global Travel Retail Website Covering Major Airports and Markets Worldwide
PMI International Launches Global Travel Retail Website Covering Major Airports and Markets Worldwide
Philip Morris International’s (PMI) Global Travel Retail (GTR) division has launched its first dedicated global website, smokefreetravel.com. The site provides adult nicotine users with information on the availability of PMI’s smoke-free products at major airports and domestic markets worldwide, supporting multi-device access.
Jul.10 by 2FIRSTS.ai
Philippines DTI Reports $740K in Illegal E-Cigarette Seizures and Removal of 100 Million Violation Records This Year
Philippines DTI Reports $740K in Illegal E-Cigarette Seizures and Removal of 100 Million Violation Records This Year
Between January and May 2025, the Philippine DTI seized $740,000 worth of illegal e-cigarettes from 88 unauthorized brands. Over 104 million online violations were removed, 628 businesses flagged, 385 legal notices issued, and 10 brands suspended.
May.28
U.S. Health Secretary Criticizes Slow FDA Action, Vows to Crack Down on Illegal Vapes
U.S. Health Secretary Criticizes Slow FDA Action, Vows to Crack Down on Illegal Vapes
U.S. Health Secretary Robert Kennedy Jr. on Wednesday criticized the FDA for slow approval of U.S.-made e-cigarettes, saying the delay has allowed Chinese products to dominate the market and target American youth. He told lawmakers he would move to remove illegal Chinese vapes.
May.16 by 2FIRSTS.ai
Osceola County, Florida Receives $400,000 from JUUL Settlement to Fund Youth Vaping Prevention Programs
Osceola County, Florida Receives $400,000 from JUUL Settlement to Fund Youth Vaping Prevention Programs
Osceola County, Florida, has received $400,000 from JUUL’s $79 million statewide settlement. The funds will be used for youth vaping prevention and nicotine addiction treatment initiatives, including school-based education programs and the installation of vaping detection devices. Advocates have welcomed the move, stressing the need for stronger harm-awareness education.
Jul.10 by 2FIRSTS.ai
FDA Launches National Priority Review Program: Drugs Aligned with U.S. Priorities May Be Approved in as Little as One Month
FDA Launches National Priority Review Program: Drugs Aligned with U.S. Priorities May Be Approved in as Little as One Month
The FDA has launched the Commissioner’s National Priority Voucher (CNPV) program, reducing the review time for certain drugs to as little as 1–2 months. While the program currently applies only to pharmaceuticals, it demonstrates the FDA’s capacity to reform its review pathways. Whether a similar mechanism could extend to tobacco products now appears to be a matter of timing and technical details.
Jun.18